SAMRAT PHARMACHEM
|
|
BOM : 530125     NSE :      | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : NA |
Mar 20,2023 |
Price(EOD): ₹ 426.30
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 132.15 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SAMRAT PHARMACHEM | -11.5% | -16.5% | -4.4% |
SUN PHARMACEUTICAL INDUSTRIES | 0.4% | -3.5% | 7.8% |
DIVIS LABORATORIES | 1.5% | -2.7% | -36.6% |
CIPLA | -0.6% | -16.3% | -17.2% |
DR REDDYS LABORATORIES | 2.1% | -1.7% | 12.5% |
TORRENT PHARMACEUTICALS | 0.1% | 0.9% | 7.5% |
ABBOTT INDIA | 4.7% | 4.4% | 20.6% |
ZYDUS LIFESCIENCES | 1.1% | -0.3% | 27.1% |
ALKEM LABORATORIES | 0.6% | -6% | -8.9% |
FUNDAMENTAL ANALYSIS OF SAMRAT PHARMACHEM
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SAMRAT PHARMACHEM
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
5.4
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 24.37 Cr
[Latest Qtr - Dec2022 - Standalone Results ] 2.81
P/B Calculated based on Book Value of Rs 46.82 Cr
[Latest Year - Mar2022 - Standalone Results ] 0.44
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Dec2022 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-50% 10% 46% |
SHARE PRICE MOMENTUM OF SAMRAT PHARMACHEM
SAMRAT PHARMACHEM vs SENSEX
DEBT OF SAMRAT PHARMACHEM
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0.16 0.3 0.39 0.28 |
- - - - |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SAMRAT PHARMACHEM
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SAMRAT PHARMACHEM
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
18.26% -57.16% -65.42% -64.56% |
51.33% -59.97% -67.6% -67.5% |
QtrlyTrend |
-4 | |
Latest Qtr: Dec2022 | ||
Quarterly Result Analysis → |
SAMRAT PHARMACHEM related INDICES
You may also like the below Video Courses
FAQ about SAMRAT PHARMACHEM
Is SAMRAT PHARMACHEM good for long term investment?
As on Mar 20,2023, the Fundamentals of SAMRAT PHARMACHEM look Strong and hence it may be good for long term investment! See Financial Performance of SAMRAT PHARMACHEM . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SAMRAT PHARMACHEM UnderValued or OverValued?
As on Mar 20,2023, SAMRAT PHARMACHEM is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of SAMRAT PHARMACHEM ?
As on Mar 20,2023, the Intrinsic Value of SAMRAT PHARMACHEM is Rs. 388.76 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 858.29
Fair Value [Median EV / Sales Model] : Rs. 388.76
Fair Value [Median Price / Sales Model] : Rs. 292.53
Estimated Median Fair Value of SAMRAT PHARMACHEM : Rs. 388.76
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is SAMRAT PHARMACHEM trading at a Premium or Discount?
As on Mar 20,2023, SAMRAT PHARMACHEM is trading at a Premium of 10% based on the estimates of Median Intrinsic Value!